Beam Q3 Loss Widens to $134.4M; $1.0B Cash Funds Runway Into Mid-2029
BEAM sits 25% above its 52-week low of $20.23.
Summary
Beam posted a $134.4M third-quarter loss ($1.28 per share) but ended September with $1.0B in cash and guided to a runway into mid-2029, covering the risto-cel BLA filing expected as early as year-end 2026.
Key Events · Earnings and Guidance · BEAM
-
Q3 Loss Widens to $134.4M
Net loss was $134.4 million, or $1.28 per share, versus $112.6 million ($1.10) a year earlier; license and collaboration revenue fell to $0.3 million from $9.7 million.
-
Cash Covers Runway Into Mid-2029
Cash, equivalents and marketable securities totaled $1.0 billion at September 30, 2026, down from $1.2 billion at December 31, 2025; with $200 million expected from the Sixth Street facility, runway extends into mid-2029.
-
Risto-cel BLA Targeted by Year-End
Beam expects updated risto-cel sickle cell data and a U.S. BLA submission as early as year-end 2026, with a commercial build-out led by new chief commercial officer Eric Foster.
-
BEAM-302 Pivotal Dosing Due 1H 2027
Enrollment and dosing continue in the global pivotal AATD cohort, with dosing completion expected in the first half of 2027; BEAM-304 PKU dosing is slated to start in early 2027.
Analysis · BEAM · Life Sciences
The balance sheet is the real story here: $1.0B in cash plus $200M expected from the Sixth Street facility funds operations into mid-2029, covering the risto-cel BLA filing expected as early as year-end 2026, BEAM-302 pivotal dosing completion in the first half of 2027, and BEAM-304 proof of concept—so no near-term financing is required. The quarter itself showed a $134.4M net loss ($1.28 per share), wider than a year ago on flat R&D and higher G&A. Revenue stays minimal ($0.3M this quarter versus $9.7M a year ago), and that widening loss is why the stock is under pressure.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BEAM was trading at $25.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $20.23 to $38.26. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.